We scan new podcasts and send you the top 5 insights daily.
Banerjee says with a KRAS mutation at progression she would likely choose avutometinib plus defactinib in the US, but for KRAS wild-type disease she would try trametinib or binimetinib first. She considers folate-receptor ADC evidence in LGSOC still anecdotal and reserves mirvetuximab after MEK/RAF therapy.
Contrary to the idea that a pan-RAS inhibitor is superior, Varistem suggests a more targeted approach. Patients should first receive an inhibitor specific to their mutation (e.g., G12D). If resistance develops via a new RAS mutation, then a broader pan-RAS inhibitor should be used, creating a more rational, sequential treatment paradigm.
In a landscape where identifying a driver mutation typically dictates using a targeted agent first-line, KRAS G12C and NRG1 fusions are notable exceptions. For these mutations, standard chemo-immunotherapy is the initial treatment, with targeted agents reserved for subsequent lines of therapy.
Susanna Banerjee reported that the RAMP-201 study achieved a 17% response rate in KRAS wild-type tumors, contrasting with historic standard of care response rates of roughly 7%. This activity demonstrates that vertical RAF-MEK clamping combined with FAK inhibition extends benefit beyond the minority of patients carrying KRAS alterations.
There is emerging evidence for sequencing KRAS inhibitors based on their mechanism. The "on-state" inhibitor Eliron-RASIB has shown a 50% response rate in patients previously treated with "off-state" inhibitors like adagrasib, suggesting that the resistance mechanism determines the effectiveness of subsequent therapy.
For BRAF V600E low-grade serous ovarian cancer patients who progress on dabrafenib/trametinib, clinicians can appeal for the KRAS-approved combination avutametinib/defactinib. This strategy is based on evidence of the drug's activity in KRAS wild-type patients, offering a rational off-label option.
In Dr Hussain’s case, two prominent gynecologic oncologists suggested hospice without mentioning avutometinib plus defactinib. Banerjee notes the FDA accelerated approval and NCCN listing are over a year old and calls for multi-prong education for all clinicians across the clinical oncology team, much like the BRCA/PARP rollout.
In the rare scenario of colorectal cancer with both HER2 amplification and a KRAS G12C mutation, US-based experts might prioritize KRAS-directed therapy. This preference is driven by durable data for KRAS inhibitors, even though choosing between targets is difficult without direct comparative studies.
Patients progressing on first-generation KRAS G12C inhibitors may still respond to subsequent KRAS-targeted agents. Newer drugs with different binding mechanisms or greater potency are showing response rates over 40% in this post-progression setting, offering a potential new line of therapy.
While the avutometanib/defactinib combination is newly approved for KRAS-mutated ovarian cancer, its significant toxicity profile—causing up to a third of patients to stop treatment—creates a clear clinical need for agents like specific KRAS inhibitors that may offer similar efficacy with better tolerability.
In KRAS-mutant low-grade serous ovarian cancer, blocking RAS-RAF-MEK signaling triggers compensatory FAK pathway upregulation as an escape mechanism. Combining the RAF/MEK clamp avutametnib with FAK inhibitor defactinib abrogates this bypass resistance, demonstrating notable activity that recently secured accelerated FDA approval.